- Home
- BRNS vs CTSO Comparison
BRNS vs CTSO Comparison
Compare BRNS & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- CTSO
- Stock Information
- Founded
- BRNS 2016
- CTSO 1997
- Country
- BRNS United Kingdom
- CTSO United States
- Employees
- BRNS N/A
- CTSO N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- CTSO Medical/Dental Instruments
- Sector
- BRNS Health Care
- CTSO Health Care
- Exchange
- BRNS Nasdaq
- CTSO Nasdaq
- Market Cap
- BRNS 55.9M
- CTSO 45.3M
- IPO Year
- BRNS 2021
- CTSO N/A
- Fundamental
- Price
- BRNS $0.75
- CTSO $0.64
- Analyst Decision
- BRNS Strong Buy
- CTSO Buy
- Analyst Count
- BRNS 1
- CTSO 2
- Target Price
- BRNS $4.00
- CTSO $5.38
- AVG Volume (30 Days)
- BRNS 111.8K
- CTSO 112.2K
- Earning Date
- BRNS 11-07-2025
- CTSO 11-13-2025
- Dividend Yield
- BRNS N/A
- CTSO N/A
- EPS Growth
- BRNS N/A
- CTSO N/A
- EPS
- BRNS N/A
- CTSO N/A
- Revenue
- BRNS N/A
- CTSO $36,979,520.00
- Revenue This Year
- BRNS N/A
- CTSO $11.93
- Revenue Next Year
- BRNS N/A
- CTSO $21.22
- P/E Ratio
- BRNS N/A
- CTSO N/A
- Revenue Growth
- BRNS 1766.46
- CTSO 20.75
- 52 Week Low
- BRNS $0.64
- CTSO $0.60
- 52 Week High
- BRNS $2.92
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- BRNS 24.92
- CTSO 24.35
- Support Level
- BRNS $0.75
- CTSO $0.60
- Resistance Level
- BRNS $0.81
- CTSO $0.70
- Average True Range (ATR)
- BRNS 0.11
- CTSO 0.06
- MACD
- BRNS -0.04
- CTSO -0.01
- Stochastic Oscillator
- BRNS 0.06
- CTSO 5.54
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.